Welcome to our dedicated page for Journey Medical news (Ticker: DERM), a resource for investors and traders seeking the latest updates and insights on Journey Medical stock.
Journey Medical Corporation develops, sells and markets FDA-approved prescription pharmaceutical products for dermatological conditions. The company is a commercial-stage dermatology pharmaceutical issuer with a portfolio of branded prescription drugs marketed in the United States.
Recurring news for DERM centers on quarterly and annual financial results, corporate updates, and commercialization progress across its dermatology portfolio. Company updates frequently discuss Emrosi™, a modified-release minocycline product approved for inflammatory lesions of rosacea in adults, including payer access, group purchasing organization contracts, prescription demand, product revenue, and clinical data presentations or publications for Emrosi/DFD-29.
Journey Medical (NASDAQ: DERM) announced a settlement with Padagis US LLC regarding patents for three key products: QBREXZA, AMZEEQ, and ZILXI. Under the agreement, Padagis cannot launch generics until August 15, 2030, July 1, 2031, and April 1, 2027, respectively. This settlement is aimed at solidifying Journey Medical's market exclusivity and supporting sales growth for these dermatological products. The CEO emphasized the importance of enforcing intellectual property rights to benefit the company, shareholders, and patients relying on these treatments.
Journey Medical Corporation (NASDAQ: DERM), a pharmaceutical company specializing in dermatology, will present at the B. Riley Securities 22nd Annual Institutional Investor Conference on May 26, 2022. CEO Claude Maraoui will provide a corporate overview at 12:20 p.m. PT and will engage in one-on-one meetings during the event. Journey Medical focuses on innovative dermatology products and currently markets nine such products. Founded by Fortress Biotech (NASDAQ: FBIO), the company is headquartered in Scottsdale, Arizona.
Journey Medical Corporation (NASDAQ: DERM) reported record revenue of $23.3 million for Q1 2022, a 117% increase compared to Q1 2021. Net product sales reached $20.8 million, up 94% year-over-year. The company initiated a pivotal Phase 3 clinical trial for DFD-29 targeting papulopustular rosacea and expects NDA filing in H2 2023. Although DERM reported a net loss of $1.4 million, its Adjusted EBITDA improved to $2.3 million. Journey Medical aims to launch another prescription product in H2 2022, underlining its growth strategy.
Journey Medical Corporation (NASDAQ: DERM) will release its Q1 2022 financial results on May 10, 2022, post-market. A conference call is scheduled for that day at 4:30 p.m. ET. Interested parties can join via dial-in or a live audio webcast, with replays available for 30 days. Journey Medical focuses on dermatological products and currently markets nine such products. The company, founded by Fortress Biotech (NASDAQ: FBIO), aims to commercialize innovative solutions in dermatology.
Journey Medical Corporation (NASDAQ: DERM) announced participation in the Fortress Biotech Virtual R&D Summit on April 5-6, 2022. The management team will present a corporate overview and engage in a panel discussion on April 5 at 1:30 p.m. ET. The event, hosted by the B. Riley Securities’ Healthcare Equity Research team, will showcase Fortress’ diverse pipeline. A webcast of the presentation will be available on Journey Medical's website for 30 days post-event. Journey Medical focuses on innovative dermatology products and has nine marketed treatments for skin conditions.
Journey Medical Corporation (NASDAQ: DERM) announced its financial results for the full year 2021, reporting a record net product revenue of $63.1 million, a 42% increase from 2020. The company also successfully completed its IPO, raising $30.6 million. DERM initiated a pivotal Phase 3 clinical program for DFD-29 aimed at treating papulopustular rosacea. Despite these advancements, the company reported a net loss of $44 million for the year, largely attributed to R&D expenses and cybersecurity losses.
Journey Medical Corporation (NASDAQ: DERM) plans to release its year-end 2021 financial results on March 23, 2022, following the U.S. market close. A conference call to discuss these results will take place on the same day at 4:30 p.m. ET. Interested individuals can participate by dialing the provided numbers or joining the live audio webcast available on the company’s website. Journey Medical focuses on the development and commercialization of dermatological products and has nine products currently in the market.
Journey Medical Corporation announced the initiation of a Phase 3 clinical trial for DFD-29 (Minocycline Modified Release Capsules) to treat papulopustular rosacea. This follows promising Phase 2 data showing DFD-29 had approximately double the efficacy of Doxycycline capsules in reducing inflammatory lesions. The trial includes two multicenter, randomized studies, each enrolling up to 320 adult patients. The primary objective is to evaluate DFD-29's safety and effectiveness compared to placebo and Doxycycline over 16 weeks. Claimed benefits could significantly enhance treatment options for the estimated 415 million global rosacea sufferers.
Journey Medical Corporation (NASDAQ: DERM) announced its participation in the 34th Annual ROTH Conference from March 13-15, 2022. CEO Claude Maraoui will present a corporate overview on March 14 at 12:00 p.m. PT, with one-on-one meetings available throughout the event. A webcast of the presentation will be accessible on Journey Medical's website for about 30 days post-conference. Journey Medical focuses on developing dermatological products, currently marketing nine solutions aimed at treating common skin conditions.
Journey Medical Corporation (NASDAQ: DERM) announced that its licensing partner, Maruho Co., Ltd., received approval from Japan's Ministry of Health for Rapifort® Wipes 2.5%, used for treating primary axillary hyperhidrosis. This milestone triggers a $10 million payment, with Journey receiving $2.5 million. The approval expands Journey's revenue beyond U.S. sales. Rapifort® Wipes is a derivative of QBREXZA, which is FDA-approved for similar use in the U.S. and recognized by the International Hyperhidrosis Society as a first-line treatment.